Synthesis and biological activities of new hydrazide derivatives

Figures & data

Scheme 1.  Synthesis of hydrazide derivatives.

Table I.  Some characteristics of the compounds.

Comp.	R1	R2	R3	R4	Yield (%)	Molecular Formula	Mol. Weight	M.P. (°C)
3-a	H	H	H	H	78	C14H11N5O	265	261-262
3-b	H	H	H	Cl	75	C14H10ClN5O	299.5	236-238
3-c	H	H	H	CH3	72	C15H13N5O	279	256-258
3-d	H	H	H	OCH3	76	C15H13N5O2	295	269-271
3-e	H	H	H	NO2	69	C14H10N6O3	310	274 dec.
3-f	H	Cl	H	H	79	C14H10ClN5O	299.5	259-260
3-g	H	CH3	H	H	71	C15H13N5O	279	228-230
3-h	H	H	Cl	H	70	C14H10ClN5O	299.5	230-232
3-i	H	H	CH3	H	69	C15H13N5O	279	212-214
3-j	H	H	H	N(CH3)2	78	C16H16N6O	308	242-244
3-k	NHCH3	H	H	H	77	C15H14N6O	294	180-182
3-l	NHCH3	H	H	Cl	75	C15H13ClN6O	328.5	234-235
3-m	NHCH3	H	H	OCH3	80	C16H16N6O2	324	216-218
3-n	NHCH3	Cl	H	H	81	C15H13ClN6O	328.5	232-234

Table II.  MIC values μg/mL of compounds 3a-n.

Compounds	A	B	C	D	E	F	G	H	I
3a	50	50	50	50	50	100	100	50	200
3b	50	50	50	50	50	100	100	50	200
3c	50	100	50	50	50	200	100	50	200
3d	50	50	50	50	50	200	100	50	200
3e	50	100	50	50	50	100	100	50	200
3f	50	100	50	100	100	200	200	50	200
3g	50	100	50	50	50	100	100	50	200
3h	50	100	50	50	50	200	100	50	200
3i	50	100	50	50	50	100	100	50	200
3j	50	50	50	50	50	100	100	50	200
3k	50	100	50	50	50	100	100	50	200
3l	50	200	50	50	100	200	200	50	200
3m	50	100	50	50	100	100	100	50	200
3n	25	100	50	50	50	100	100	50	200
Reference-1	12.50	12.50	12.50	50	12.50	50	50	–	–
Reference-2	–	–	–	–	–	–	–	50	100

Reference-1: Chloramphenicol, Reference-2: Ketoconazole, A: Escherichia coli (NRRL B-3704), B: Staphylococcus aureus (NRRL B-767), C: Salmonella typhimurium (NRRL B-4420), D: Proteus vulgaris (NRLL B-123), E: Enterococcus faecalis (isolated obtained from Faculty of Medicine Osmangazi University, Eskisehir, Turkey), F: Pseudomonas aeruginosa (NRRL B-23 27853), G: Klebsiella spp. (isolated obtained from Osmangazi Uni. Fac.of Medicine, Eskisehir, Turkey), H: Candida albicans (isolates obtained from Osmangazi Uni. Fac.of Medicine, Eskisehir, Turkey), I: Candida glabrata (isolates obtained from Osmangazi Uni. Fac.of Medicine, Eskisehir, Turkey).

Table III.  Antituberculosis activity of compounds 3a-n.

Compounds	Dose used (μg/mL)	% inhibition
3a	6.25	22
3b	6.25	38
3c	6.25	17
3d	6.25	30
3e	6.25	31
3f	6.25	45
3g	6.25	41
3h	6.25	36
3i	6.25	44
3j	6.25	86
3k	6.25	18
3l	6.25	20
3m	6.25	13
3n	6.25	48
Rifampicin	0.25	98